Neurogene Inc. Files 8-K with Regulatory Disclosures
Ticker: NGNE · Form: 8-K · Filed: May 7, 2024 · CIK: 1404644
Sentiment: neutral
Topics: regulatory-disclosure, financial-statements, exhibits
TL;DR
Neurogene Inc. filed a standard 8-K on May 7th, no major news but check exhibits for details.
AI Summary
Neurogene Inc. filed an 8-K on May 7, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleukin Therapeutics, Inc., is based in New York, NY, and operates in the Pharmaceutical Preparations industry. This filing does not contain specific financial figures or transaction details beyond its classification.
Why It Matters
This 8-K filing indicates that Neurogene Inc. is making required disclosures to the SEC, which is standard practice for publicly traded companies and provides transparency to investors.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for regulatory disclosure and exhibits, not indicating any immediate material events or risks.
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- Neoleukin Therapeutics, Inc. (company) — Former company name
- May 7, 2024 (date) — Date of earliest event reported
- New York, NY (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing for Neurogene Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits, as indicated by the filing's item information.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on May 7, 2024.
What was Neurogene Inc. formerly known as?
Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc.
In which industry does Neurogene Inc. operate?
Neurogene Inc. operates in the Pharmaceutical Preparations industry, with Standard Industrial Classification code 2834.
Where are Neurogene Inc.'s principal executive offices located?
Neurogene Inc.'s principal executive offices are located at 535 W 24th Street, 5th Floor, New York, NY 10011.
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-05-07 06:20:01
Key Financial Figures
- $0.000001 — ange on which registered Common Stock, $0.000001 par value NGNE The Nasdaq Global Market
Filing Documents
- ngne-20240507.htm (8-K) — 27KB
- ngne_asgctpresentationxfin.htm (EX-99.1) — 26KB
- image_0a.jpg (GRAPHIC) — 3KB
- 0001404644-24-000049.txt ( ) — 188KB
- ngne-20240507.xsd (EX-101.SCH) — 2KB
- ngne-20240507_lab.xml (EX-101.LAB) — 22KB
- ngne-20240507_pre.xml (EX-101.PRE) — 13KB
- ngne-20240507_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On May 7, 2024, Neurogene Inc. (the "Company") issued a press release announcing that the initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome was presented at the American Society for Gene and Cell Therapy Annual Meeting, demonstrating that its NGN-401 gene therapy candidate has been generally well tolerated by all three patients dosed with three, six and nine-month follow up. A copy of the press release announcing this presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated May 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: May 7, 2024 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer